These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21306248)

  • 1. Safety of recombinant activated factor VII in randomized clinical trials.
    Yank V; Stafford RS
    N Engl J Med; 2011 Feb; 364(6):575; author reply 575-6. PubMed ID: 21306248
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of recombinant activated factor VII in randomized clinical trials.
    Patel A; Cooper N; Laffan MA
    N Engl J Med; 2011 Feb; 364(6):574; author reply 575-6. PubMed ID: 21306250
    [No Abstract]   [Full Text] [Related]  

  • 3. Off-label use of recombinant activated factor VII--safe or not safe?
    Aledort LM
    N Engl J Med; 2010 Nov; 363(19):1853-4. PubMed ID: 21047230
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety of recombinant activated factor VII in randomized clinical trials.
    Arellano-Rodrigo E
    N Engl J Med; 2011 Feb; 364(6):574-5; author reply 575-6. PubMed ID: 21306249
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety of recombinant activated factor VII in randomized clinical trials.
    Franchini M; Targher G; Lippi G
    N Engl J Med; 2011 Feb; 364(6):575; author reply 575-6. PubMed ID: 21306247
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety of recombinant activated factor VII in randomized clinical trials.
    Levi M; Levy JH; Andersen HF; Truloff D
    N Engl J Med; 2010 Nov; 363(19):1791-800. PubMed ID: 21047223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant factor VIIa for unlicensed indications--a definite No or a cautious Maybe in selected patients?
    Sorour Y; Van Veen JJ; Makris M
    Int J Clin Pract; 2010 Oct; 64(11):1468-1471. PubMed ID: 20722768
    [No Abstract]   [Full Text] [Related]  

  • 8. Off-label use of recombinant activated coagulation factor VII for bleeding may raise the risk of arterial thrombosis.
    Ferrari L; Podda GM
    Intern Emerg Med; 2011 Jun; 6(3):261-2. PubMed ID: 21541718
    [No Abstract]   [Full Text] [Related]  

  • 9. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications.
    Yank V; Tuohy CV; Logan AC; Bravata DM; Staudenmayer K; Eisenhut R; Sundaram V; McMahon D; Olkin I; McDonald KM; Owens DK; Stafford RS
    Ann Intern Med; 2011 Apr; 154(8):529-40. PubMed ID: 21502651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-label use of recombinant factor VIIa.
    Phillips A
    Ann Intern Med; 2011 Sep; 155(5):337; author reply 338-9. PubMed ID: 21893633
    [No Abstract]   [Full Text] [Related]  

  • 11. Off-label use of recombinant factor VIIa.
    Hayanga AJ
    Ann Intern Med; 2011 Sep; 155(5):337-8; author reply 338-9. PubMed ID: 21893632
    [No Abstract]   [Full Text] [Related]  

  • 12. Recombinant factor VIIa is a pan-hemostatic agent?
    Aledort LM
    Thromb Haemost; 2000 May; 83(5):637-8. PubMed ID: 10823252
    [No Abstract]   [Full Text] [Related]  

  • 13. Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients.
    Guzzetta NA; Russell IA; Williams GD
    Anesth Analg; 2012 Aug; 115(2):364-78. PubMed ID: 22652310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A hemorrhage of off-label use.
    Avorn J; Kesselheim A
    Ann Intern Med; 2011 Apr; 154(8):566-7. PubMed ID: 21502655
    [No Abstract]   [Full Text] [Related]  

  • 15. A hemorrhage of off-label use.
    Karkouti K; Levy JH
    Ann Intern Med; 2011 Sep; 155(5):339; author reply 339-40. PubMed ID: 21893634
    [No Abstract]   [Full Text] [Related]  

  • 16. Change of coagulation after NovoSeven® use for bleeding during cardiac surgery.
    Tomita E; Takase H; Tajima K; Suematsu Y
    Asian Cardiovasc Thorac Ann; 2017 Feb; 25(2):99-104. PubMed ID: 28114794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant activated factor VII for bleeding in patients without inherited bleeding disorders.
    Selin S; Tejani A
    Issues Emerg Health Technol; 2006 Mar; (82):1-4. PubMed ID: 16602203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Judicious Use of Recombinant Factor VIIa.
    Goodnough LT; Levy JH
    Semin Thromb Hemost; 2016 Mar; 42(2):125-32. PubMed ID: 26838698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting.
    Logan AC; Goodnough LT
    Hematology Am Soc Hematol Educ Program; 2010; 2010():153-9. PubMed ID: 21239786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No evidence or no alternative? Taking responsibility for off-label prescribing.
    Ghinea N; Lipworth W; Kerridge I; Day R
    Intern Med J; 2012 Mar; 42(3):247-51. PubMed ID: 22432984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.